<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6385">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01023308</url>
  </required_header>
  <id_info>
    <org_study_id>CLBH589D2308</org_study_id>
    <secondary_id>2009-015507-52</secondary_id>
    <nct_id>NCT01023308</nct_id>
  </id_info>
  <brief_title>Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma</brief_title>
  <acronym>PANORAMA-1</acronym>
  <official_title>A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Panobinostat (LBH589) is a highly potent pan-deacetylase inhibitor (pan-DACi), inclusive of
      HDAC6, which disrupts aggresome function, promotes accumulation of cytotoxic misfolded
      protein aggregates and triggers myeloma cell death. Combination of pan-DAC and protease
      inhibition by co-treatment with panobinostat (PAN) and bortezomib (BTZ) has demonstrated
      synergistic cytotoxicity in vitro and in vivo in pre-clinical experiments. Furthermore,
      clinical experience in advanced multiple myeloma (MM) patients treated by oral panobinostat
      and i.v bortezomib ± dexamethasone showed very encouraging results for efficacy and
      manageable toxicity profile.

      Given the medical need for improved treatment strategies for patients with previously
      treated and relapsed MM, the purpose of this prospective, multinational, randomized,
      double-blind, placebo-controlled, parallel group Phase III study is to compare the results
      in progression-free survival of 2 combination therapies, panobinostat with bortezomib and
      dexamethasone or placebo with bortezomib and dexamethasone, in patients with previously
      treated MM whose disease has recurred or progressed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free Survival Events in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.</measure>
    <time_frame>45 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.</measure>
    <time_frame>45 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.</measure>
    <time_frame>45 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Best overall response based on mEBMT criteria per investigator assessment:
Stringent complete response (sCR): CR as defined below plus:
Normal FLC ratio and Absence of clonal cells in bone marrow Complete response: Negative immunofixation on serum and urine and Disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in bone marrow Very good partial reaponse:Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein plus urine M-protein level &lt;100 mg per 24 h Partial response: ≥50% reduction of serum M-protein ≥90% urine M-protein reduction or &lt;200 mg/24 h ≥50% decrease in soft-tissue plasmacytomas Stable disease: Not meeting criteria for CR, VGPR, PR or progressive disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response Per Investigator Assessment (mEBMT Criteria) of Response Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.</measure>
    <time_frame>45 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response Per Investigator Assessment (mEBMT Criteria) Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.</measure>
    <time_frame>45 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression/Relapse Per Investigator Assessment (mEBMT Criteria) Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.</measure>
    <time_frame>45 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>EBMT criteria to assess myeloma response:
Complete Response (CR)-absence of serum and urine monoclonal paraprotein for 6 weeks, plus no increase in size or number of lytic bone lesions, plus other factors)
Partial Response (PR)-not all CR criteria, plus &gt;=50% reduction in serum monoclonal paraprotein plus others
Minimal Response (MR)- 25-49% reduction in serum monoclonal paraprotein plus others
Stable Disease (SD)- not MR or progressive disease (PD)
Progressive Disease (PD)- reappearance of monoclonal paraprotein, lytic bone lesions, other
Not Evaluable (NE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organization for Research and Treatment of Cancer Multiple Myeloma Module( EORTC QLQ-MY20) -Change From Baseline by Treatment Group</measure>
    <time_frame>12, 24 and 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Higher values in the disease symptoms and side effects of treatment scores indicate worsening. Higher scores in the future perspective and body image scores indicate improvement. LS Means and SEM are estimated from the repeated measures model. Following factors and covariates are included in the repeated measurement model: time, treatment, treatment by time interaction, number of prior lines of anti-MM therapy (1/ 2 and 3), prior use of BTZ (Yes/ No), baseline score.Disease Symptom is the sum of 20 questions, total score ranges from 0 (best possible outcome) to 100 (worst possible outcome)&quot;, All subscales of EORTC QLQ-MY20 have the same score range of 0 -100. Decrease in symptom scores from baseline indicate improvement in symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organization for Research and Treatment of Cancer Quality of Life Questionaire : EORTC QLQ-C30 - Summary Statistics by Treatment Group</measure>
    <time_frame>12, 24 and 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The EORTC QLQ-C30 measures functional dimensions (physical, role, emotional, cognitive, and social), three multi-item symptom scales (fatigue, nausea/vomiting, and pain), six single-item symptom scales (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea and financial impact) and a global health status/QoL scale. Disease Symptom is the sum of 30 questions, total score ranges from 0 (best possible outcome) to 100 (worst possible outcome)&quot;, All subscales of EORTC QLQ-C30 have the same score range of 0 -100. For global health status and other functional scales, an increase from baseline indicates improvement of QoL. Whereas for symptoms scales, fatigue, dyspnea, insomnia, appetite loss, constipation and diarrhea, decrease in scores from baseline indicate improvement in symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FACT/GOG-NTX-Change From Baseline by Treatment Group</measure>
    <time_frame>12, 24 and 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The FACT/GOG-NTX was developed from the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System and focuses on four general quality of life domains for physical well being, functional well-being, social/family well-being, and emotional well-being, and includes additional items to characterize treatment-related neurotoxicity. Higher subscales/total scores represent higher QOL. In the case of the neurotoxicity subscale, lower scores correspond to higher neurotoxicity. The recall period referenced in the questionnaire is the past 7 days.Ranges for FACT-G subscales are as follows:.PWB, SWB and FWB scale 0 -28, EWB scale 0-24, NtxS scale 0-44, FACT/GOG-Ntx trial outcome index scale is 0-100 and FACT-G scale is also scaled 0-100. An increase from baseline in these scores indicate improvement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">768</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Panobinostat + Bortezomib + Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panobinostat was given 20 mg hard gelatin capsules . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV)injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Bortezomib + Dexamethasone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo was given as a hard gelatin capsule in the image of Panobinostat . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV) injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panobinostat</intervention_name>
    <arm_group_label>Panobinostat + Bortezomib + Dexamethasone</arm_group_label>
    <other_name>LBH589</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <arm_group_label>Panobinostat + Bortezomib + Dexamethasone</arm_group_label>
    <arm_group_label>Placebo + Bortezomib + Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient has a previous diagnosis of multiple myeloma.

          2. Patient requires retreatment for multiple myeloma

          3. Patient has measurable M component in serum or urine at study screening

        Exclusion Criteria:

          1. Patient who has progressed under all prior lines of anti MM therapy

          2. Patient who has been treated by bortezomib before, and did not reach at least a minor
             response under this therapy, or progressed under it or within 60 days of last dose

          3. Patient has shown intolerance to bortezomib or to dexamethasone or components of
             these drugs or has any contraindication to one or the other drug , following locally
             applicable prescribing information

          4. Patient received prior treatment with DAC inhibitors including panobinostat

          5. Patient has impaired cardiac function, or a prolonged QTc interval at screening ECG

          6. Patient taking medications with relative risk of prolonging the QT interval or
             inducing Torsade de pointes

          7. Female patient who is pregnant or breast feeding or with childbearing potential and
             not willing to use a double method of contraception up to 3 months after the end of
             study treatment. Male patient who is not willing to use a barrier method of
             contraception up to 3 months after the end of study treatment.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Oncology Associates Tucson (Carondelet &amp; Wilmot)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rau, Subramanyam</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Cancer Research</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Permanente Medical Group SC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - California Southern Kaiser Permanente SCPMG</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Onc Dept</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boca Raton Community Hospital SC</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Specialist of Palm Beaches</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Medical Research of South Florida Dept.ofInnovativeMedResearch</name>
      <address>
        <city>Miami Shores</city>
        <state>Florida</state>
        <zip>33138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Cancer &amp; Blood Center, LLC</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthWest Georgia Oncology Centers NW Georgia Oncology Centers PC</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Marywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quincy Medical Group</name>
      <address>
        <city>Quincy</city>
        <state>Illinois</state>
        <zip>62301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Agnes Hospital Healthcare Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Oncology/Hematology, P.C.</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newland Medical Associates, PC Newland Medical - Southfield</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hubert H. Humphrey Cancer Center - Coon Rapids</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, P.A. Minnesota Oncology-Hematology</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Missouri Cancer Associates Dept.ofMissouriCancerAssoc.</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Orange VA Medical Center SC</name>
      <address>
        <city>East Orange</city>
        <state>New Jersey</state>
        <zip>07018-1095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Kisco Medical Group</name>
      <address>
        <city>Mt. Kisco</city>
        <state>New York</state>
        <zip>10549</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Pharma Research</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton CCOP</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Signal Point Hematology Oncology, Inc.</name>
      <address>
        <city>Middletown</city>
        <state>Ohio</state>
        <zip>45042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Pennsylvania Cancer Institute /Western Penn Hospital Western Pann. Cancer Inst.</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharma Resource</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Univeristy SC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of the High Plains</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center/University of Texas MD Anderson CC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Basin Hematology SC</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute SC</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary Medical Center</name>
      <address>
        <city>Walla Walla</city>
        <state>Washington</state>
        <zip>33962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University/ Mary Babb Randolph Cancer Center</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>B1900AWT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1114AAN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000JHQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Franston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Linz</city>
        <zip>A-4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brasilia</city>
        <state>DF</state>
        <zip>70710.904</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20.211-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20551-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>22640-102</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barretos</city>
        <state>SP</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13083-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01224-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Olomouc</city>
        <state>CZE</state>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno - Bohunice</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague 2</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Odense</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vejle</city>
        <zip>DK-7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ålborg</city>
        <zip>DK-9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Århus</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alexandria</city>
        <zip>21131</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Giza</city>
        <zip>11451</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>HUS Helsinki</city>
        <zip>FIN-00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Turku</city>
        <zip>FIN-20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Blois Cedex</city>
        <zip>41016</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>LILLE Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Limoges cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nantes</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75231</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Strasbourg cedex</city>
        <zip>67085</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Saarow</city>
        <zip>155226</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bamberg</city>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duisburg</city>
        <zip>47166</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81737</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <state>GR</state>
        <zip>570 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>115 28</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong SAR</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kfar-Sava</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>FG</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lecce</city>
        <state>LE</state>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pescara</city>
        <state>PE</state>
        <zip>65124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reggio Calabria</city>
        <state>RC</state>
        <zip>89124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pagani</city>
        <state>SA</state>
        <zip>84016</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya-city</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>790-8524</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ogaki-city</city>
        <state>Gifu</state>
        <zip>503-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shibukawa</city>
        <state>Gunma</state>
        <zip>377-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kure</city>
        <state>Hiroshima</state>
        <zip>737-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Higashiibaraki-gun</city>
        <state>Ibaraki</state>
        <zip>311-3193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Okayama-city</city>
        <state>Okayama</state>
        <zip>701-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka-city</city>
        <state>Osaka</state>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suita-city</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shibuya</city>
        <state>Tokyo</state>
        <zip>150-8935</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Niigata</city>
        <zip>951-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hwasun-gun</city>
        <state>Jeollanam-do</state>
        <zip>519-809</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>110 744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Busan</city>
        <zip>602-812</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suwon</city>
        <zip>442-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taegu</city>
        <zip>700 - 721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beirut</city>
        <zip>6301</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Luis Potosí</city>
        <zip>78218</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergen</city>
        <zip>NO-5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fredrikstad</city>
        <zip>NO-1603</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kristiansand</city>
        <zip>NO-4605</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Skien</city>
        <zip>NO-3710</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trondheim</city>
        <zip>NO-7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saratov</city>
        <zip>410028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>191024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parktown</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pretoria</city>
        <zip>0027</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <state>Andalucia</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla y Leon</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Laguna</city>
        <state>Las Palmas de Gran Canaria</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Sebastian</city>
        <state>Pais Vasco</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Linköping</city>
        <zip>SE-581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Luleå</city>
        <zip>SE-971 80</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Niaosong Township</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34303</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>WC1E 6HX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Egypt</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Lebanon</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://NovartisClinicalTrials.com</url>
  </link>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 21, 2015</lastchanged_date>
  <firstreceived_date>November 30, 2009</firstreceived_date>
  <firstreceived_results_date>March 23, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloma</keyword>
  <keyword>DACi</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Combination,</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Panobinostat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participant flow is based on the Full analysis set consists of all randomized patients.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Panobinostat + Bortezomib + Dexamethasone</title>
          <description>Panobinostat was given 20 mg hard gelatin capsules . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV)injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
        </group>
        <group group_id="P2">
          <title>Placebo + Bortezomib + Dexamethasone</title>
          <description>Placebo was given as a hard gelatin capsule in the image of Panobinostat . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV) injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="387"/>
                <participants group_id="P2" count="381"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102">completed all planned cycles of study treatment as per protocol</participants>
                <participants group_id="P2" count="102">completed all planned cycles of study treatment as per protocol</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="285"/>
                <participants group_id="P2" count="279"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Abnormal test proceedure results</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="153"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>New Cancer therapy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Untreated</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Panobinostat + Bortezomib + Dexamethasone</title>
          <description>Panobinostat was given 20 mg hard gelatin capsules . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV)injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
        </group>
        <group group_id="B2">
          <title>Placebo + Bortezomib + Dexamethasone</title>
          <description>Placebo was given as a hard gelatin capsule in the image of Panobinostat . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV) injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="387"/>
                <measurement group_id="B2" value="381"/>
                <measurement group_id="B3" value="768"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="62.4" spread="9.34"/>
                <measurement group_id="B2" value="61.8" spread="9.43"/>
                <measurement group_id="B3" value="62.1" spread="9.38"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="185"/>
                <measurement group_id="B2" value="176"/>
                <measurement group_id="B3" value="361"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="202"/>
                <measurement group_id="B2" value="205"/>
                <measurement group_id="B3" value="407"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Caucasian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="249"/>
                <measurement group_id="B2" value="250"/>
                <measurement group_id="B3" value="499"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="128"/>
                <measurement group_id="B2" value="104"/>
                <measurement group_id="B3" value="232"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="22"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival Events in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.</title>
        <time_frame>45 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Panobinostat + Bortezomib + Dexamethasone</title>
            <description>Panobinostat was given 20 mg hard gelatin capsules . Bortezomib was given at 1.3 mg/m^2 as a 3 to 5 second bolus intravenous (IV)injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Bortezomib + Dexamethasone</title>
            <description>Placebo was given as a hard gelatin capsule in the image of Panobinostat . Bortezomib was given at 1.3 mg/m^2 as a 3 to 5 second bolus intravenous (IV) injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="387"/>
                  <measurement group_id="O2" value="381"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Progression-free Survival Events in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.</title>
            <units>number of events</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="207"/>
                  <measurement group_id="O2" value="260"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.</title>
        <time_frame>45 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Panobinostat + Bortezomib + Dexamethasone</title>
            <description>Panobinostat was given 20 mg hard gelatin capsules . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV)injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Bortezomib + Dexamethasone</title>
            <description>Placebo was given as a hard gelatin capsule in the image of Panobinostat . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV) injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="387"/>
                  <measurement group_id="O2" value="381"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Progression Free Survival in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.</title>
            <units>months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11.99" lower_limit="10.32" upper_limit="12.94"/>
                  <measurement group_id="O2" value="8.80" lower_limit="7.56" upper_limit="9.23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.</title>
        <description>Best overall response based on mEBMT criteria per investigator assessment:
Stringent complete response (sCR): CR as defined below plus:
Normal FLC ratio and Absence of clonal cells in bone marrow Complete response: Negative immunofixation on serum and urine and Disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in bone marrow Very good partial reaponse:Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein plus urine M-protein level &lt;100 mg per 24 h Partial response: ≥50% reduction of serum M-protein ≥90% urine M-protein reduction or &lt;200 mg/24 h ≥50% decrease in soft-tissue plasmacytomas Stable disease: Not meeting criteria for CR, VGPR, PR or progressive disease</description>
        <time_frame>45 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Panobinostat + Bortezomib + Dexamethasone</title>
            <description>Panobinostat was given 20 mg hard gelatin capsules . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV)injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Bortezomib + Dexamethasone</title>
            <description>Placebo was given as a hard gelatin capsule in the image of Panobinostat . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV) injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="387"/>
                  <measurement group_id="O2" value="381"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Overall Response Rate in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.</title>
            <description>Best overall response based on mEBMT criteria per investigator assessment:
Stringent complete response (sCR): CR as defined below plus:
Normal FLC ratio and Absence of clonal cells in bone marrow Complete response: Negative immunofixation on serum and urine and Disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in bone marrow Very good partial reaponse:Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein plus urine M-protein level &lt;100 mg per 24 h Partial response: ≥50% reduction of serum M-protein ≥90% urine M-protein reduction or &lt;200 mg/24 h ≥50% decrease in soft-tissue plasmacytomas Stable disease: Not meeting criteria for CR, VGPR, PR or progressive disease</description>
            <units>% participants with response</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60.7"/>
                  <measurement group_id="O2" value="54.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Response Per Investigator Assessment (mEBMT Criteria) of Response Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.</title>
        <time_frame>45 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Panobinostat + Bortezomib + Dexamethasone</title>
            <description>Panobinostat was given 20 mg hard gelatin capsules . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV)injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Bortezomib + Dexamethasone</title>
            <description>Placebo was given as a hard gelatin capsule in the image of Panobinostat . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV) injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="387"/>
                  <measurement group_id="O2" value="381"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Response Per Investigator Assessment (mEBMT Criteria) of Response Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.</title>
            <units>months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.51" lower_limit="1.41" upper_limit="1.64"/>
                  <measurement group_id="O2" value="2.00" lower_limit="1.61" upper_limit="2.79"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response Per Investigator Assessment (mEBMT Criteria) Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.</title>
        <time_frame>45 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Panobinostat + Bortezomib + Dexamethasone</title>
            <description>Panobinostat was given 20 mg hard gelatin capsules . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV)injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Bortezomib + Dexamethasone</title>
            <description>Placebo was given as a hard gelatin capsule in the image of Panobinostat . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV) injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="235"/>
                  <measurement group_id="O2" value="208"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Duration of Response Per Investigator Assessment (mEBMT Criteria) Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.</title>
            <units>duration of response in months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="13.14" lower_limit="11.76" upper_limit="14.92"/>
                  <measurement group_id="O2" value="10.87" lower_limit="9.23" upper_limit="11.76"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression/Relapse Per Investigator Assessment (mEBMT Criteria) Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.</title>
        <description>EBMT criteria to assess myeloma response:
Complete Response (CR)-absence of serum and urine monoclonal paraprotein for 6 weeks, plus no increase in size or number of lytic bone lesions, plus other factors)
Partial Response (PR)-not all CR criteria, plus &gt;=50% reduction in serum monoclonal paraprotein plus others
Minimal Response (MR)- 25-49% reduction in serum monoclonal paraprotein plus others
Stable Disease (SD)- not MR or progressive disease (PD)
Progressive Disease (PD)- reappearance of monoclonal paraprotein, lytic bone lesions, other
Not Evaluable (NE).</description>
        <time_frame>45 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Panobinostat + Bortezomib + Dexamethasone</title>
            <description>Panobinostat was given 20 mg hard gelatin capsules . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV)injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Bortezomib + Dexamethasone</title>
            <description>Placebo was given as a hard gelatin capsule in the image of Panobinostat . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV) injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="387"/>
                  <measurement group_id="O2" value="381"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Progression/Relapse Per Investigator Assessment (mEBMT Criteria) Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.</title>
            <description>EBMT criteria to assess myeloma response:
Complete Response (CR)-absence of serum and urine monoclonal paraprotein for 6 weeks, plus no increase in size or number of lytic bone lesions, plus other factors)
Partial Response (PR)-not all CR criteria, plus &gt;=50% reduction in serum monoclonal paraprotein plus others
Minimal Response (MR)- 25-49% reduction in serum monoclonal paraprotein plus others
Stable Disease (SD)- not MR or progressive disease (PD)
Progressive Disease (PD)- reappearance of monoclonal paraprotein, lytic bone lesions, other
Not Evaluable (NE).</description>
            <units>months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12.71" lower_limit="11.30" upper_limit="14.06"/>
                  <measurement group_id="O2" value="8.54" lower_limit="7.66" upper_limit="9.72"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>European Organization for Research and Treatment of Cancer Multiple Myeloma Module( EORTC QLQ-MY20) -Change From Baseline by Treatment Group</title>
        <description>Higher values in the disease symptoms and side effects of treatment scores indicate worsening. Higher scores in the future perspective and body image scores indicate improvement. LS Means and SEM are estimated from the repeated measures model. Following factors and covariates are included in the repeated measurement model: time, treatment, treatment by time interaction, number of prior lines of anti-MM therapy (1/ 2 and 3), prior use of BTZ (Yes/ No), baseline score.Disease Symptom is the sum of 20 questions, total score ranges from 0 (best possible outcome) to 100 (worst possible outcome)&quot;, All subscales of EORTC QLQ-MY20 have the same score range of 0 -100. Decrease in symptom scores from baseline indicate improvement in symptoms.</description>
        <time_frame>12, 24 and 48 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Panobinostat + Bortezomib + Dexamethasone</title>
            <description>Panobinostat was given 20 mg hard gelatin capsules . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV)injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Bortezomib + Dexamethasone</title>
            <description>Placebo was given as a hard gelatin capsule in the image of Panobinostat . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV) injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="387"/>
                  <measurement group_id="O2" value="381"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>European Organization for Research and Treatment of Cancer Multiple Myeloma Module( EORTC QLQ-MY20) -Change From Baseline by Treatment Group</title>
            <description>Higher values in the disease symptoms and side effects of treatment scores indicate worsening. Higher scores in the future perspective and body image scores indicate improvement. LS Means and SEM are estimated from the repeated measures model. Following factors and covariates are included in the repeated measurement model: time, treatment, treatment by time interaction, number of prior lines of anti-MM therapy (1/ 2 and 3), prior use of BTZ (Yes/ No), baseline score.Disease Symptom is the sum of 20 questions, total score ranges from 0 (best possible outcome) to 100 (worst possible outcome)&quot;, All subscales of EORTC QLQ-MY20 have the same score range of 0 -100. Decrease in symptom scores from baseline indicate improvement in symptoms.</description>
            <units>score on a scale</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Disease Symptom wk 12 change baseline (n=215,243)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-4.795" lower_limit="-6.76" upper_limit="-2.83"/>
                  <measurement group_id="O2" value="-4.865" lower_limit="-6.75" upper_limit="-2.98"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Disease Symptom wk 24 change baseline (n=148,177)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-4.401" lower_limit="-6.53" upper_limit="-2.27"/>
                  <measurement group_id="O2" value="-6.797" lower_limit="-8.79" upper_limit="-4.81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Disease Symptom wk 48 change baseline (n=37,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.836" lower_limit="-6.76" upper_limit="-1.084"/>
                  <measurement group_id="O2" value="-6.626" lower_limit="-11.1" upper_limit="-2.12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Side effects of treatment wk 12 chge (n=213,242)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.162" lower_limit="6.510" upper_limit="9.814"/>
                  <measurement group_id="O2" value="5.524" lower_limit="3.933" upper_limit="7.115"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Side effects of treatment wk 24 chge (n=148,175)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.016" lower_limit="6.955" upper_limit="11.08"/>
                  <measurement group_id="O2" value="7.731" lower_limit="5.795" upper_limit="9.668"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Side effects of treatment wk 48 chge (n=37,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.357" lower_limit="0.442" upper_limit="6.273"/>
                  <measurement group_id="O2" value="3.654" lower_limit="0.352" upper_limit="6.956"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Future perspective wk 12 chge (n=214,242)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.319" lower_limit="2.893" upper_limit="7.744"/>
                  <measurement group_id="O2" value="6.194" lower_limit="3.854" upper_limit="8.533"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Future perspective wk 24 chge (n=148,176)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.877" lower_limit="0.977" upper_limit="6.778"/>
                  <measurement group_id="O2" value="5.839" lower_limit="3.103" upper_limit="8.575"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Future perspective wk 48 chge (n=37,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.331" lower_limit="-.142" upper_limit="8.804"/>
                  <measurement group_id="O2" value="6.951" lower_limit="1.807" upper_limit="12.10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Body image wk 12 chge (n=213,240)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-7.178" lower_limit="-10.5" upper_limit="-3.87"/>
                  <measurement group_id="O2" value="-6.22" lower_limit="-9.41" upper_limit="-3.03"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Body image wk 24 chge (n=147,175)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-11.463" lower_limit="-15.3" upper_limit="-7.66"/>
                  <measurement group_id="O2" value="-7.358" lower_limit="-10.9" upper_limit="-3.81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Body image wk 48 chge (n=37,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.161" lower_limit="-7.73" upper_limit="3.410"/>
                  <measurement group_id="O2" value="-4.666" lower_limit="-11.1" upper_limit="1.729"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>European Organization for Research and Treatment of Cancer Quality of Life Questionaire : EORTC QLQ-C30 - Summary Statistics by Treatment Group</title>
        <description>The EORTC QLQ-C30 measures functional dimensions (physical, role, emotional, cognitive, and social), three multi-item symptom scales (fatigue, nausea/vomiting, and pain), six single-item symptom scales (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea and financial impact) and a global health status/QoL scale. Disease Symptom is the sum of 30 questions, total score ranges from 0 (best possible outcome) to 100 (worst possible outcome)&quot;, All subscales of EORTC QLQ-C30 have the same score range of 0 -100. For global health status and other functional scales, an increase from baseline indicates improvement of QoL. Whereas for symptoms scales, fatigue, dyspnea, insomnia, appetite loss, constipation and diarrhea, decrease in scores from baseline indicate improvement in symptoms.</description>
        <time_frame>12, 24 and 48 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Panobinostat + Bortezomib + Dexamethasone</title>
            <description>Panobinostat was given 20 mg hard gelatin capsules . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV)injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Bortezomib + Dexamethasone</title>
            <description>Placebo was given as a hard gelatin capsule in the image of Panobinostat . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV) injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="387"/>
                  <measurement group_id="O2" value="381"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>European Organization for Research and Treatment of Cancer Quality of Life Questionaire : EORTC QLQ-C30 - Summary Statistics by Treatment Group</title>
            <description>The EORTC QLQ-C30 measures functional dimensions (physical, role, emotional, cognitive, and social), three multi-item symptom scales (fatigue, nausea/vomiting, and pain), six single-item symptom scales (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea and financial impact) and a global health status/QoL scale. Disease Symptom is the sum of 30 questions, total score ranges from 0 (best possible outcome) to 100 (worst possible outcome)&quot;, All subscales of EORTC QLQ-C30 have the same score range of 0 -100. For global health status and other functional scales, an increase from baseline indicates improvement of QoL. Whereas for symptoms scales, fatigue, dyspnea, insomnia, appetite loss, constipation and diarrhea, decrease in scores from baseline indicate improvement in symptoms.</description>
            <units>score on a scale</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Global health wk 12 change baseline (n=216,239)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-9.853" lower_limit="-12.50" upper_limit="-7.20"/>
                  <measurement group_id="O2" value="-4.044" lower_limit="-6.60" upper_limit="-1.49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Global health wk 24 change baseline (n=150,176)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-7.867" lower_limit="-10.7" upper_limit="-5.08"/>
                  <measurement group_id="O2" value="-1.518" lower_limit="-4.11" upper_limit="-1.075"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Global health wk 48 change baseline (n=38,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.986" lower_limit="-7.21" upper_limit="1.237"/>
                  <measurement group_id="O2" value="4.345" lower_limit="-0.416" upper_limit="9.106"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Physical functioning wk 12 chge (n=217,242)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-9.67" lower_limit="-12.00" upper_limit="-7.38"/>
                  <measurement group_id="O2" value="-5.393" lower_limit="-76.3" upper_limit="-3.16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Physical functioning wk 24 chge (n=151,177)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-9.516" lower_limit="-12.20" upper_limit="-7.38"/>
                  <measurement group_id="O2" value="-6.456" lower_limit="-8.98" upper_limit="-3.93"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Physical functioning wk 48 chge (n=38,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.88" lower_limit="-6.41" upper_limit="0.651"/>
                  <measurement group_id="O2" value="2.037" lower_limit="-2.07" upper_limit="6.147"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Role functioning wk 12 chge (n=215,237)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-11.159" lower_limit="-14.6" upper_limit="-7.74"/>
                  <measurement group_id="O2" value="-6.762" lower_limit="-10.1" upper_limit="-3.45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Role functioning wk 24 chge (n=150,176)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-11.875" lower_limit="-15.7" upper_limit="-8.01"/>
                  <measurement group_id="O2" value="-11.263" lower_limit="-14.9" upper_limit="-7.61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Role functioning wk 48 chge (n=38,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-5.927" lower_limit="-11.4" upper_limit="-0.424"/>
                  <measurement group_id="O2" value="-0.401" lower_limit="-6.73" upper_limit="5.924"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cognitive functioning wk 12 chge (n=216,240)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-4.464" lower_limit="-6.89" upper_limit="-2.04"/>
                  <measurement group_id="O2" value="-1.023" lower_limit="-3.36" upper_limit="1.318"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cognitive functioning wk 24 chge (n=149,176)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-6.053" lower_limit="-8.87" upper_limit="-3.24"/>
                  <measurement group_id="O2" value="-3.542" lower_limit="-6.22" upper_limit="-0.865"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cognitive functioning wk 48 chge (n=38,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-5.568" lower_limit="-9.79" upper_limit="-1.34"/>
                  <measurement group_id="O2" value="-4.042" lower_limit="-8.99" upper_limit="0.902"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Social functioning wk 12 chge (n=216,240)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-8.502" lower_limit="-11.6" upper_limit="-5.44"/>
                  <measurement group_id="O2" value="-3.991" lower_limit="-6.97" upper_limit="1.02"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Social functioning wk 24 chge (n=148,171)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-8.925" lower_limit="-12.4" upper_limit="-5.42"/>
                  <measurement group_id="O2" value="-6.338" lower_limit="-9.66" upper_limit="-3.02"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Social functioning wk 48 chge (n=37,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-6.104" lower_limit="-11.0" upper_limit="-1.22"/>
                  <measurement group_id="O2" value="4.617" lower_limit="-0.930" upper_limit="10.16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue wk 12 chge (n=217,241)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15.122" lower_limit="12.27" upper_limit="17.98"/>
                  <measurement group_id="O2" value="7.939" lower_limit="5.174" upper_limit="10.70"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue wk 24 chge (n=151,176)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12.677" lower_limit="9.419" upper_limit="15.94"/>
                  <measurement group_id="O2" value="9.203" lower_limit="6.136" upper_limit="12.27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue wk 48 chge(n=38,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.646" lower_limit="0.086" upper_limit="9.206"/>
                  <measurement group_id="O2" value="-2.625" lower_limit="-7.88" upper_limit="2.628"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dyspnea wk 12 chge (n=217,240)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.964" lower_limit="10.60" upper_limit="17.33"/>
                  <measurement group_id="O2" value="6.266" lower_limit="3.012" upper_limit="9.521"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dyspnea wk 24 chge (n=151,177)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.939" lower_limit="4.639" upper_limit="11.24"/>
                  <measurement group_id="O2" value="5.308" lower_limit="2.221" upper_limit="8.394"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dyspnea wk 48 chge (n=38,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.118" lower_limit="-1.58" upper_limit="9.813"/>
                  <measurement group_id="O2" value="2.82" lower_limit="-3.88" upper_limit="9.523"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Insomnia wk 12 chge (n=216,239)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.283" lower_limit="2.851" upper_limit="9.715"/>
                  <measurement group_id="O2" value="7.625" lower_limit="4.331" upper_limit="10.92"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Insomnia wk 24 chge (n=149,176)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.023" lower_limit="6.038" upper_limit="14.01"/>
                  <measurement group_id="O2" value="6.104" lower_limit="2.381" upper_limit="9.827"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Insomnia wk 48 chge (n=38,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.464" lower_limit="-8.74" upper_limit="3.811"/>
                  <measurement group_id="O2" value="-3.442" lower_limit="-10.9" upper_limit="4.017"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Appetite loss wk 12 chge (n=217,239)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15.167" lower_limit="11.60" upper_limit="18.74"/>
                  <measurement group_id="O2" value="5.383" lower_limit="1.925" upper_limit="8.841"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Appetite loss wk 24 chge (n=151,176)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.574" lower_limit="12.39" upper_limit="20.76"/>
                  <measurement group_id="O2" value="5.861" lower_limit="1.918" upper_limit="9.804"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Appetite loss wk 48 chge (n=38,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.999" lower_limit="-2.08" upper_limit="10.07"/>
                  <measurement group_id="O2" value="-2.963" lower_limit="-9.99" upper_limit="4.061"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Constipation wk 12 chge (n=215,240)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.135" lower_limit="0.667" upper_limit="7.603"/>
                  <measurement group_id="O2" value="6.42" lower_limit="3.104" upper_limit="9.735"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Constipation wk 24 chge (n=151,177)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.153" lower_limit="-3.64" upper_limit="3.337"/>
                  <measurement group_id="O2" value="0.524" lower_limit="-2.73" upper_limit="5.782"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Constipation wk 48 chge (n=38,25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.358" lower_limit="-5.57" upper_limit="4.851"/>
                  <measurement group_id="O2" value="-0.946" lower_limit="-7.26" upper_limit="5.373"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea wk 12 chge (n=217,241)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18.888" lower_limit="15.04" upper_limit="22.74"/>
                  <measurement group_id="O2" value="10.206" lower_limit="6.452" upper_limit="13.96"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea wk 24 chge (n=150,177)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23.163" lower_limit="18.46" upper_limit="27.87"/>
                  <measurement group_id="O2" value="16.406" lower_limit="11.98" upper_limit="20.83"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea wk 48 chge (n=38,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.48" lower_limit="14.02" upper_limit="26.94"/>
                  <measurement group_id="O2" value="10.996" lower_limit="3.422" upper_limit="18.57"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Emotional function chge wk 12 (n=217,240)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.90" lower_limit="-5.28" upper_limit="-.052"/>
                  <measurement group_id="O2" value="-0.40" lower_limit="-2.72" upper_limit="1.92"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Emotional function chge wk 24 (n=150,176)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.26" lower_limit="-4.90" upper_limit="0.37"/>
                  <measurement group_id="O2" value="-0.28" lower_limit="-2.77" upper_limit="2.22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Emotional function chge wk 48 (n=38,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.43" lower_limit="-3.93" upper_limit="4.78"/>
                  <measurement group_id="O2" value="4.09" lower_limit="-0.97" upper_limit="9.15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nausea/vomiting chge wk 12 (n=217,239)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.12" lower_limit="4.00" upper_limit="8.24"/>
                  <measurement group_id="O2" value="0.71" lower_limit="-1.33" upper_limit="2.75"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nausea/vomiting chge wk 24 (n=151,177)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.07" lower_limit="2.00" upper_limit="6.14"/>
                  <measurement group_id="O2" value="0.42" lower_limit="-1.54" upper_limit="2.38"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nausea/vomiting chge wk 48 (n=38,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.88" lower_limit="-2.03" upper_limit="3.78"/>
                  <measurement group_id="O2" value="-2.235" lower_limit="-5.67" upper_limit="1.20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain chge wk 12 (n= 217, 240)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.47" lower_limit="-3.56" upper_limit="2.63"/>
                  <measurement group_id="O2" value="0.82" lower_limit="-2.18" upper_limit="3.82"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain chge wk 24 (n= 150, 175)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.07" lower_limit="-1.38" upper_limit="5.51"/>
                  <measurement group_id="O2" value="-2.39" lower_limit="-5.63" upper_limit="0.85"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain chge wk 48 (n= 38, 26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.03" lower_limit="-5.35" upper_limit="5.30"/>
                  <measurement group_id="O2" value="-8.31" lower_limit="-14.60" upper_limit="-2.06"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Financial difficulties chge wk 12 (n=215,239)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-4.87" lower_limit="-7.71" upper_limit="-2.03"/>
                  <measurement group_id="O2" value="-3.23" lower_limit="-5.97" upper_limit="-0.49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Financial difficulties chge wk 24 (n=148,174)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.74" lower_limit="-3.96" upper_limit="2.47"/>
                  <measurement group_id="O2" value="-5.88" lower_limit="-8.97" upper_limit="-2.80"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Financial difficulties chge wk 48 (n=37,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.77" lower_limit="-8.65" upper_limit="1.10"/>
                  <measurement group_id="O2" value="-6.29" lower_limit="-11.90" upper_limit="-0.65"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FACT/GOG-NTX-Change From Baseline by Treatment Group</title>
        <description>The FACT/GOG-NTX was developed from the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System and focuses on four general quality of life domains for physical well being, functional well-being, social/family well-being, and emotional well-being, and includes additional items to characterize treatment-related neurotoxicity. Higher subscales/total scores represent higher QOL. In the case of the neurotoxicity subscale, lower scores correspond to higher neurotoxicity. The recall period referenced in the questionnaire is the past 7 days.Ranges for FACT-G subscales are as follows:.PWB, SWB and FWB scale 0 -28, EWB scale 0-24, NtxS scale 0-44, FACT/GOG-Ntx trial outcome index scale is 0-100 and FACT-G scale is also scaled 0-100. An increase from baseline in these scores indicate improvement.</description>
        <time_frame>12, 24 and 48 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Panobinostat + Bortezomib + Dexamethasone</title>
            <description>Panobinostat was given 20 mg hard gelatin capsules . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV)injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Bortezomib + Dexamethasone</title>
            <description>Placebo was given as a hard gelatin capsule in the image of Panobinostat . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV) injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="387"/>
                  <measurement group_id="O2" value="381"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>FACT/GOG-NTX-Change From Baseline by Treatment Group</title>
            <description>The FACT/GOG-NTX was developed from the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System and focuses on four general quality of life domains for physical well being, functional well-being, social/family well-being, and emotional well-being, and includes additional items to characterize treatment-related neurotoxicity. Higher subscales/total scores represent higher QOL. In the case of the neurotoxicity subscale, lower scores correspond to higher neurotoxicity. The recall period referenced in the questionnaire is the past 7 days.Ranges for FACT-G subscales are as follows:.PWB, SWB and FWB scale 0 -28, EWB scale 0-24, NtxS scale 0-44, FACT/GOG-Ntx trial outcome index scale is 0-100 and FACT-G scale is also scaled 0-100. An increase from baseline in these scores indicate improvement.</description>
            <units>score on a scale</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Neurotoxicity wk 12 change baseline (n=212,240)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-4.481" lower_limit="-5.33" upper_limit="-3.63"/>
                  <measurement group_id="O2" value="-3.337" lower_limit="-4.17" upper_limit="-2.50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Neurotoxicity wk 24 change baseline (n=148,174)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-4.564" lower_limit="-5.49" upper_limit="-3.64"/>
                  <measurement group_id="O2" value="-4.739" lower_limit="-5.61" upper_limit="-3.86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Neurotoxicity wk 48 change baseline (n=35,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.158" lower_limit="-4.52" upper_limit="-1.79"/>
                  <measurement group_id="O2" value="-2.133" lower_limit="-3.64" upper_limit="-0.627"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Physical wellbeing wk 12 chge (n=215,240)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.29" lower_limit="-3.94" upper_limit="-2.64"/>
                  <measurement group_id="O2" value="-1.952" lower_limit="-2.58" upper_limit="-1.32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Physical wellbeingwk 24 chge (n=150,176)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.044" lower_limit="-3.74" upper_limit="-2.35"/>
                  <measurement group_id="O2" value="-2.259" lower_limit="-2.92" upper_limit="-1.60"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Physical wellbeing wk 48 chge (n=38,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.037" lower_limit="-3.08" upper_limit="-0.992"/>
                  <measurement group_id="O2" value="0.203" lower_limit="-1.03" upper_limit="1.439"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Trial Outcomes wk 12 chge (n=209,236)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-10.573" lower_limit="-12.2" upper_limit="-8.86"/>
                  <measurement group_id="O2" value="-6.874" lower_limit="-8.55" upper_limit="-5.19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Trial Outcomes wk 24 chge (n=148,173)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-9.84" lower_limit="-11.7" upper_limit="-7.98"/>
                  <measurement group_id="O2" value="-8.894" lower_limit="-10.7" upper_limit="-7.13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Trial Outcomes wk 48 chge (n=35,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-6.633" lower_limit="-9.28" upper_limit="-3.98"/>
                  <measurement group_id="O2" value="-2.821" lower_limit="-5.76" upper_limit="0.122"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FACT-G Total wk 12 chge (n=213,240)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-6.658" lower_limit="-8.23" upper_limit="-5.09"/>
                  <measurement group_id="O2" value="-4.106" lower_limit="-5.64" upper_limit="-2.57"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FACT-G Totalwk 24 chge (n=147,175)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-6.076" lower_limit="-7.84" upper_limit="-4.31"/>
                  <measurement group_id="O2" value="-4.609" lower_limit="-6.30" upper_limit="-2.92"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FACT-G Total wk 48 chge (n=37,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.704" lower_limit="-5.29" upper_limit="-0.118"/>
                  <measurement group_id="O2" value="-1.435" lower_limit="-4.42" upper_limit="1.547"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FACT/GOGNTX Total wk 12 chge (n=206,230)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-11.176" lower_limit="-13.3" upper_limit="-9.03"/>
                  <measurement group_id="O2" value="-7.524" lower_limit="-9.64" upper_limit="-5.41"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FACT/GOGNTX Total wk 24 chge (n=146,172)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-10.581" lower_limit="-12.9" upper_limit="-8.23"/>
                  <measurement group_id="O2" value="-9.179" lower_limit="-9.64" upper_limit="-5.41"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FACT/GOGNTX Total wk 48 chge (n=35,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-5.871" lower_limit="-9.24" upper_limit="-2.50"/>
                  <measurement group_id="O2" value="-3.151" lower_limit="-6.92" upper_limit="0.614"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Functional Well-being chge wk 12 (n=213,241)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.56" lower_limit="-3.16" upper_limit="-1.96"/>
                  <measurement group_id="O2" value="-1.60" lower_limit="-2.18" upper_limit="-1.42"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Functional Well-being chge wk 24 (n=150,176)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.40" lower_limit="-3.08" upper_limit="-1.72"/>
                  <measurement group_id="O2" value="-2.06" lower_limit="-2.70" upper_limit="-1.42"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Functional Well-being chge wk 48 (n=38,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.21" lower_limit="-2.25" upper_limit="-0.17"/>
                  <measurement group_id="O2" value="-1.10" lower_limit="-2.20" upper_limit="0.18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Social/Family Well-being chge wk 12 (n=215,240)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.58" lower_limit="-1.12" upper_limit="-0.04"/>
                  <measurement group_id="O2" value="-0.73" lower_limit="-1.24" upper_limit="-0.15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Social/Family Well-being chge wk 24 (n=151,176)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.53" lower_limit="-1.15" upper_limit="0.10"/>
                  <measurement group_id="O2" value="-0.24" lower_limit="-0.83" upper_limit="0.35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Social/Family Well-being chge wk 48 (n=38,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.75" lower_limit="-1.57" upper_limit="0.08"/>
                  <measurement group_id="O2" value="-0.73" lower_limit="-1.66" upper_limit="0.19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Emotional Well-being chge wk 12 (n=208,237)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.02" lower_limit="-0.49" upper_limit="0.44"/>
                  <measurement group_id="O2" value="0.36" lower_limit="-0.09" upper_limit="0.81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Emotional Well-being chge wk 24 (n=147,173)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.01" lower_limit="-0.50" upper_limit="0.52"/>
                  <measurement group_id="O2" value="0.21" lower_limit="-0.28" upper_limit="0.69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Emotional Well-being chge wk 48 (n=37,26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.09" lower_limit="0.28" upper_limit="1.90"/>
                  <measurement group_id="O2" value="0.06" lower_limit="-0.87" upper_limit="0.99"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were collected for the safety population, the participants who took at least one dose of the interventions. Efficacy analysis were performed onthe FAS</desc>
      <group_list>
        <group group_id="E1">
          <title>PAN+BTZ+Dex</title>
          <description>Panobinostat was given 20 mg hard gelatin capsules . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV)injection. Dexamethasone was given as an oral dose of 20 mg/day.</description>
        </group>
        <group group_id="E2">
          <title>PBO+BTZ+Dex</title>
          <description>Placebo was given as a hard gelatin capsule in the image of Panobinostat . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV) injection. Dexamethasone was given as an oral dose of 20 mg/day..</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="228" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="157" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hyperviscosity syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Monocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Exophthalmos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Necrotising oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Peritoneal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Haemophilus sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pneumonia haemophilus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pseudomonal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Viral haemorrhagic cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>General physical condition abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypochloraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Osteonecrosis of jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Autonomic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Brain compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Central nervous system haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Central nervous system necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cranial nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hyperreflexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Sensory loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypomania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypoventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Orthopnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acute febrile neutrophilic dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="379" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="366" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="238" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="150" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="254" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="155" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="155" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
